Filtered By:
Procedure: Hemodialysis
Therapy: Dialysis

This page shows you your search results in order of relevance. This is page number 10.

Order by Relevance | Date

Total 299 results found since Jan 2013.

Incidence and risk factors of cognitive dysfunction in hemodialysis patients: A systematic review and meta-analysis
CONCLUSIONS: The most important risk factors for cognitive dysfunction associated with hemodialysis might be female gender, old age, diabetes, and stroke. Close attention should be paid to such patients for early prevention.PMID:37592399 | DOI:10.1111/sdi.13171
Source: Seminars in Dialysis - August 18, 2023 Category: Urology & Nephrology Authors: Jun Liu Kehong Chen Jia Chen Lili Fu Weiwei Zhang Jing Lin Jingfang Wan Source Type: research

RCTs: Peginesatide in patients with anaemia and chronic kidney disease
Source: N Engl J Med Area: News In the New England Journal of Medicine, researchers report the results of four event-driven, randomised, controlled, open-label trials that compared the efficacy and safety of standard erythropoiesis-stimulating agent (ESA) therapy with peginesatide (Omontys), a peptide based ESA approved in the US in March 2012 for the treatment of anaemia caused by chronic kidney disease in adults who are undergoing dialysis.   The EMERALD 1 and EMERALD 2 studies involved patients undergoing haemodialysis. Cardiovascular safety was evaluated by analysis of an adjudicated composite safety end poin...
Source: NeLM - News - January 24, 2013 Category: Drugs & Pharmacology Source Type: news

Frequency of and risk factors for poor cognitive performance in hemodialysis patients
Conclusions: There is a high frequency of poor cognitive performance in hemodialysis patients, primarily affecting executive function. Risk factors for worse executive function include vascular risk factors as well as vascular disease. Normal performance on the MMSE does not preclude impaired cognitive function, because individuals with MMSE score ≥24 also have a high frequency of poor cognitive performance.
Source: Neurology - January 28, 2013 Category: Neurology Authors: Sarnak, M. J., Tighiouart, H., Scott, T. M., Lou, K. V., Sorensen, E. P., Giang, L. M., Drew, D. A., Shaffi, K., Strom, J. A., Singh, A. K., Weiner, D. E. Tags: All Cerebrovascular disease/Stroke, Memory, Neuropsychological assessment, Executive function ARTICLE Source Type: research

Blood Pressure Recordings During Hemodialysis Access Interventions: Implications for Acute Management
Abstract A retrospective study evaluating the pattern of blood pressure and its related complications before, during, and after percutaneous hemodialysis interventions was performed in patients presenting with asymptomatic hypertension. Hemodialysis patients undergoing percutaneous interventions including tunneled hemodialysis catheter insertion, percutaneous balloon angioplasty and thrombectomy procedure, and stage II hypertension (systolic blood pressure ≥160 mmHg) were included in this analysis. Blood pressure medications were not used while midazolam and fentanyl were routinely administered. Patients were followed f...
Source: Seminars In Dialysis - March 28, 2013 Category: Hematology Authors: Arif Asif, Hector Castro, Ahmed Ameen Waheed, Vishesh Kumar, Syed S Haqqie, Gary Siskin, Roy O Mathew, Darius Mason, Tushar Vachharajani, Ali Nayer, Donna Merrill, Muhammad UT Akmal, Loay Salman Tags: Investigation Source Type: research

Case report: hemodialysis for dabigatran overdose
3 out of 5 stars Hemodialysis for the Treatment of Pulmonary Hemorrhage from Dabigatran Overdose. Chen BC et al. Am J Kidney Dis 2013 Apr 15 [Epub ahead of print] Abstract Dabigatran (Pradaxa) is a competitive direct thrombin inhibitor approved in the United States for stroke prophylaxis in patients with nonvalvular atrial fibrillation. Although dabigatran has certain advantages over coumadin related to issues of dosing and testing, there is no readily available test to measure its anticoagulation effect, and there is no antidote to reverse bleeding. Recommendations for treating a patient with dabigatran-associated hemorr...
Source: The Poison Review - April 24, 2013 Category: Toxicology Authors: Leon Tags: Medical dabigatran hemodialysis hemorrhage overdose Source Type: news

Hypertension in CKD
Conclusions: Compared to pre-HD blood pressure, home blood pressure seemed to be better in predicting mortality and cardiovascular outcomes.
Source: Nephrology Dialysis Transplantation - May 10, 2013 Category: Urology & Nephrology Authors: Iseki, K., Arima, H., Poulikakos, D., Banerjee, D., Malik, M. Tags: Abstracts Source Type: research

Kidney disease and cognitive function.
Abstract We provide a brief review of research on chronic kidney disease and cognitive performance, including dementia. We touch briefly on the literature relating end-stage-renal disease to cognitive function, but focus on studies of modest and moderate forms of chronic kidney disease (CKD) that precede dialysis and transplantation. We summarize previous reviews dealing with case control studies of patients but more fully examine community-based studies with large samples and necessary controls for demographic risk factors, cardiovascular variables, and other confounds such as depression. In addition we suggest p...
Source: Contributions to Nephrology - May 26, 2013 Category: Urology & Nephrology Authors: Elias MF, Dore GA, Davey A Tags: Contrib Nephrol Source Type: research

Extracorporeal Therapy for Dabigatran Removal in the Treatment of Acute Bleeding: A Single Center Experience.
CONCLUSIONS: Extracorporeal therapy lowered dabigatran concentrations, suggesting that it removed the drug and may effectively accelerate total clearance, especially in patients with impaired kidney function. The use of prolonged intermittent hemodialysis or intermittent hemodialysis followed by continuous renal replacement therapy is recommended for the management of life-threatening bleeding in patients receiving dabigatran. The advantage of extracorporeal therapy should be weighed against the risk of bleeding with catheter insertion. PMID: 23704302 [PubMed - as supplied by publisher]
Source: Clinical Journal of the American Society of Nephrology : CJASN - May 23, 2013 Category: Urology & Nephrology Authors: Singh T, Maw TT, Henry BL, Pastor-Soler NM, Unruh ML, Hallows KR, Nolin TD Tags: Clin J Am Soc Nephrol Source Type: research

Blood Pressure Recordings During Hemodialysis Access Interventions: Implications for Acute Management.
Abstract A retrospective study evaluating the pattern of blood pressure and its related complications before, during, and after percutaneous hemodialysis interventions was performed in patients presenting with asymptomatic hypertension. Hemodialysis patients undergoing percutaneous interventions including tunneled hemodialysis catheter insertion, percutaneous balloon angioplasty and thrombectomy procedure, and stage II hypertension (systolic blood pressure ≥160 mmHg) were included in this analysis. Blood pressure medications were not used while midazolam and fentanyl were routinely administered. Patients were f...
Source: Seminars in Dialysis - March 28, 2013 Category: Urology & Nephrology Authors: Asif A, Castro H, Waheed AA, Kumar V, Haqqie SS, Siskin G, Mathew RO, Mason D, Vachharajani T, Nayer A, Merrill D, Akmal MU, Salman L Tags: Semin Dial Source Type: research

Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial
Conclusions BP-lowering treatment with an ARB did not significantly lower the risks of major cardiovascular events or death among patients with hypertension on chronic HD. (Cochrane Renal Group Prospective Trial Register number CRG010600030).
Source: Nephrology Dialysis Transplantation - June 18, 2013 Category: Urology & Nephrology Authors: Iseki, K., Arima, H., Kohagura, K., Komiya, I., Ueda, S., Tokuyama, K., Shiohira, Y., Uehara, H., Toma, S., on behalf of the Olmesartan Clinical Trial in Okinawan Patients Under OKIDS (OCTOPUS) Group, Tomiyama, Arima, Chinen, Tokashiki, Hirano-Nakasone, N Tags: Intra- and Extracorporeal Treatment of Kidney Failure Source Type: research

Serum n-3 and n-6 Polyunsaturated Fatty Acid Profile as an Independent Predictor of Cardiovascular Events in Hemodialysis Patients
Conclusions: In hemodialysis patients, serum PUFA profile is unfavorably altered, and the low n-3-PUFA:AA ratios are independent predictors of CVD.
Source: American Journal of Kidney Diseases - April 19, 2013 Category: Urology & Nephrology Authors: Tetsuo Shoji, Ryusuke Kakiya, Tomoshige Hayashi, Yoshihiro Tsujimoto, Mika Sonoda, Hideaki Shima, Katsuhito Mori, Shinya Fukumoto, Hideki Tahara, Atushi Shioi, Tsutomu Tabata, Masanori Emoto, Yoshiki Nishizawa, Masaaki Inaba Tags: Dialysis Source Type: research

The association of Klotho gene polymorphism with the mortality of patients on maintenance dialysis.
Abstract Despite medical progress, high morbidity and mortality rates have persisted in patients with end-stage renal disease (ESRD). The role in atherosclerosis and cardiovascular disease of klotho, an aging process-related gene, has been highlighted. Genetic variation in klotho has been reported to be a risk factor for coronary artery disease and ischemic stroke. Regarding the significance of cardiovascular disease for the outcome of ESRD patients, we investigated whether genetic variation of klotho was associated with mortality in ESRD patients on hemodialysis. 478 patients on maintenance hemodialysis for more ...
Source: Clinical Nephrology - September 2, 2013 Category: Urology & Nephrology Authors: Ko GJ, Lee YM, Lee EA, Lee JE, Bae SY, Park SW, Park MS, Pyo HJ, Kwon YJ Tags: Clin Nephrol Source Type: research

Do higher dialysate calcium concentrations increase vascular stiffness in haemodialysis patients as measured by aortic pulse wave velocity?
Background: Haemodialysis patients have an increased prevalence of hypertension and risk of cardiovascular mortality and stroke. Higher dialysate calcium concentrations have been reported to cause both an acute and chronic increase in arterial stiffness. We therefore looked at changes in arterial stiffness in established haemodialysis patients to determine whether there was a threshold effect of dialysate calcium concentration linked to change in arterial stiffness. Methods: We performed pulse wave velocity measurements six months apart in patients dialysing with calcium concentrations of 1.0, 1.25, 1.35 and>=1.5 mmol/l. R...
Source: BMC Nephrology - September 8, 2013 Category: Urology & Nephrology Authors: Evangelia CharitakiAndrew Davenport Source Type: research

HMG CoA reductase inhibitors (statins) for dialysis patients.
CONCLUSIONS: Statins have little or no beneficial effects on mortality or cardiovascular events and uncertain adverse effects in adults treated with dialysis despite clinically relevant reductions in serum cholesterol levels. PMID: 24022428 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - September 11, 2013 Category: Journals (General) Authors: Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Nigwekar SU, Hegbrant J, Strippoli GF Tags: Cochrane Database Syst Rev Source Type: research